Ryan Constantine, PhD
Retina Specialist · Redmond, ORNPI 1932527199
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by AbbVie at 35.1% of the total. Reporting peaked in 2019 at $2,173 and has fallen 92.9% since, to $155 in 2025.
Across 60 payments — averaging $86.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Roche TCRC, Inc.$1K
- Genentech USA, Inc.$773
- Genentech, Inc.$452
- Regeneron Healthcare Solutions, Inc.$368
- Alimera Sciences, Inc.$109
- plus $279 from 5 others
What the payments were for
- Consulting fees$1,60031%
- Travel & lodging$1,05820%
- Food & beverage$2,53649%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 7 | $1,822 |
| Roche TCRC, Inc. | 3 | $1,391 |
| Genentech USA, Inc. | 23 | $773 |
| Genentech, Inc. | 6 | $452 |
| Regeneron Healthcare Solutions, Inc. | 11 | $368 |
| Alimera Sciences, Inc. | 1 | $109 |
| Hoffmann-la Roche Limited | 1 | $99 |
| Astellas Pharma US Inc | 3 | $79 |
| Apellis Pharmaceuticals, Inc. | 3 | $65 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $18 |
| Kala Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$1,391
- Lucentis$116
- YUTIQ$109
- Iluvien$109
- EYLEA$104
How this compares
$5,195 in reported general payments places this provider in the 75th percentile of 36 retina specialist providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 77 | $4,287 |
| Difluprednate | 34 | $3,641 |
| MoxifloxacinMoxifloxacin Hcl | 97 | $2,196 |
| Ketorolac Tromethamine | 28 | $1,390 |
| Brimonidine Tartrate | 11 | $889 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 29 | $453 |
| Latanoprost | 23 | $245 |
| ErythromycinErythromycin Base | 19 | $205 |
| Ofloxacin | 19 | $198 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Redmond
- Christopher AdermanTroutdale$211K
- Brian Chan KaiPortland$155K
- Peter KarthNorth Bend$119K
- John HyattAshland$57K
- Brandon LujanPortland$33K
- Andreas LauerPortland$17K
- Albert EdwardsEugene$9K
- Sirichai PasadhikaPortland$6K
- David WilsonPortland$5K
- Timothy GardHillsboro$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.